Jane Parks
Pulmonary Disease · Athens, GANPI 1164418661
Payments from drug & device makers
Across 134 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$506
- Insmed, Inc.$409
- AstraZeneca$255
- Boehringer Ingelheim$232
- Grifols USA, LLC$184
- Harmony Biosciences LLC$149
- plus $789 from 21 others
What the payments were for
- Food & beverage$2,26090%
- Education$26410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 29 | $506 |
| Insmed, Inc. | 15 | $409 |
| AstraZeneca | 16 | $255 |
| Boehringer Ingelheim | 12 | $232 |
| Grifols USA, LLC | 11 | $184 |
| Harmony Biosciences LLC | 8 | $149 |
| Jazz Pharmaceuticals Inc. | 4 | $84 |
| Mylan Specialty L.p. | 5 | $84 |
| Sunovion Pharmaceuticals Inc. | 5 | $73 |
| Advanced Respiratory, Inc | 4 | $70 |
| Genentech USA, Inc. | 5 | $68 |
| Philips North America LLC | 3 | $58 |
| Mallinckrodt Hospital Products Inc. | 2 | $56 |
| Livanova USA, Inc. | 1 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Baxter Healthcare | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Sanofi | 1 | $21 |
| Novartis | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| AbbVie | 1 | $16 |
| Merck | 1 | $15 |
| Ambu Inc. | 1 | $14 |
| Electromed, Inc. | 1 | $12 |
| Inogen, Inc. | 1 | $12 |
How this compares
$2,525 in reported general payments places this provider in the 30th percentile of 365 pulmonary disease providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $51,017 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,288 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,608 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $420 |
| Roflumilast | 11 | $201 |
| Montelukast Sodium | 20 | $170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $506 | $55,62576 claims |
| Boehringer IngelheimStiolto Respimat | $232 | $5,28811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Athens
- Nehal BhattAthens$371K
- Karan JulkaAthens$94K
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.